Dr Reddys Laboratories has launched the authorized generic version of GlaxoSmithKline’s Imitrex tablets of 25 mg, 50 mg and 10 mg strength in United States. The generic Sumatriptan Succinate is indicated for the acute treatment of migraine attacks in adults, and its patented product sale value was US$ 1.29 billion in the Calendar Year 2007.
In October 2006, Dr Reddys Laboratories and Glaxo had settled the patent litigation with respect to this molecule, but the financial terms and conditions of the settlement were not disclosed. Being the only other company, apart from the originator, to launch the billion dollar product will give significant upside to Dr Reddy’s.
Dr Reddys Laboratories reported 40% fall in net profit to Rs 178.60 crore on 25% rise in sales to Rs 3057.20 crore in the six months ended September 2008.